Medical Morphine Market is Driven by Increasing Morphine Consumption in the US

27 February 2019, The global Medical Morphine Market is expected to reach USD 13.32 billion by 2024, driven by increasing morphine consumption in the U.S. The increasing prevalence of arthritis and cancer in geriatric patients is projected to impact the morphine market globally positively.

North America dominated the market by contributing more than 75.0% of the share in 2016 and continue to dominate owing to the increasing number of prescriptions for morphine in the U.S. North American market for the same is expected to grow at a CAGR of 2.9% over the forecast period. However, lack of availability of medical morphine in countries such as India is expected to hamper the growth of the market.

In terms of route of administration, the oral segment is expected to grow at the fastest CAGR over the projected period owing to its dose accuracy, high accessibility, and ease of carrying compared to injectables and other counterparts.

On the basis of indication, others segment is expected to grow at the fastest CAGR of 3.1% over the forecast period owing to increasing number of prescriptions of morphine in U.S. for nominal conditions. The cancer segment is expected to exhibit lucrative growth due to increasing prevalence of bone cancer globally.

Browse Details of Report @ https://www.hexaresearch.com/research-report/medical-morphine-market

Morphine with its use in therapeutics is also one of the most abused drug globally. Respective governments are introducing initiatives to prevent substance abuse and decrease death rates caused by morphine.

Furthermore, researchers are concentrating on drug abuse treatment for opioid addicts which is expected to reduce the illicit use of morphine. For instance, in August 2017, researchers at University of California San Diego in collaboration with CARI therapeutics commenced development of a biosensor capable of detecting opioids in human bodies.

Hexa Research has segmented the global medical morphine market based on Route of Administration , Indication and region:

Segmentation by Route of Administration, 2014 - 2024 (USD Million)
• Oral
• Injectables
• Others

Segmentation by Indication, 2014 - 2024 (USD Million)
• Cancer
• Arthritis
• Others

Segmentation by Region, 2014 - 2024 (USD Million)
• North America
    • U.S.
• Europe
    • Germany
• Asia Pacific
    • China
    • India
• Rest of the World

Key players analyzed
• Mallinckrodt Pharmaceuticals
• Alcaliber S.A.
• Purdue Pharma L.P.
• Pfizer Inc.
• Johnson Matthey Fine Chemicals
• Sun Pharmaceutical Industries Ltd.
• Verve Health Care Ltd.
• Taj Pharmaceuticals Limited
• NORTHEAST PHARM
• MANUS AKTTEVA BIOPHARMA LLP

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com

Breast Imaging Equipment Market - Global Industry Size, Analysis and Trends

19 February 2019, The global Breast Imaging Equipment Market is expected to grow at a fast pace over the forecast period (from 2012 to 2020). Growing occurrences of chronic ailments such as breast cancer are anticipated to drive product demand. Breast imaging equipment helps capture images of breast tissues to diagnose breast cancer. Rising awareness along with rapid innovations in technology is expected to boost the market in the forthcoming years.

With continuous technological developments, breast imaging devices are becoming increasingly digitalized and efficient in disease diagnosis. Factors such as high screening costs, stringent regulatory approval, low medical reimbursement procedures, and insufficient screening expertise are likely to hinder industry growth. Computer-aided diagnosis is expected to gain popularity in the worldwide market over the forecast period. Developing countries such as China, India, South Korea, and Brazil possess considerable market potential on account of high outsourcing rate and medical tourism.

Browse Details of Report @ https://www.hexaresearch.com/research-report/breast-imaging-equipment-industry

The global Breast Imaging Equipment Market is divided into products and regions. Products include breast MRI, nuclear imaging, mammography, tomosynthesis, bioelectric images, breast ultrasound, and scintimammography. Mammography is an extensively used method for detecting breast cancer. It is also considered the standard technique for diagnosis and screening. It uses very low doses of X-ray to capture 2D images of human breasts and reduces the adverse effects after screening. The second most preferred method is breast ultrasound; used for breast cancer testing. This segment may grow at a healthy rate over the forecast period due to its effectiveness in identifying breast tumors & cancers by examining the stiffness in tissues. Breast MRI is also a very efficient method because it identifies probable anomalies by examining the densities of breast tissues.

Geographically the worldwide Breast Imaging Equipment Market is categorized into Europe, North America, Asia-Pacific (APAC), and RoW. North America was the leading regional market in 2013 in terms of revenue. This growth was attributed to the presence of high-end technology, high awareness levels about breast cancer diagnosis & treatment, and a rapidly growing female geriatric population.
Europe is the second largest regional industry. The region may exhibit substantial growth till 2020 due to an expanding target based population and high investments in sunk cost. APAC is also likely to grow rapidly on account of several healthcare reforms coupled with excellent government support. Some of the major companies in the global industry are Siemens Healthcare Corp.; Aurora Imaging Technologies Inc.; GE Healthcare Ltd.; and Dilon Technologies Inc. Most of these market players adopt various business strategies, such as acquisitions, joint venture, NDP, geographical expansions, etc. in order to thrive and prosper in the long run.

A new device has been developed for 3D breast imaging by expert researchers at Dilon Technologies (Department of Energy's Thomas Jefferson National Accelerator Facility) and at the University of Florida (Department of Biomedical Engineering). Utilized in conjunction with mammography, nuclear medicine-based imaging is presently being employed as a secondary screening tool. This is done in order to decrease the number of erroneous positive results in women that have dense breasts and are at a greater risk of developing breast cancer.

Related Category Reports @ https://www.hexaresearch.com/research-category/medical-imaging-industry

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - https://www.hexaresearch.com/

Breast Cancer Market - Global Industry Size, Share, Analysis Report, 2025

19 February 2019, The global Breast Cancer Market is anticipated to witness a significant growth over the forecast period on account of growing target population base across the globe, rising prevalence of the disease, unhealthy lifestyle, exposure to radiations, and lack of physical exercises. Moreover, increasing efforts taken by major organizations across various regions to increase awareness levels is estimated to drive the market. Rising investments in R&D by various government and private organizations for development of effective drugs and treatments is also projected to play a key role in the market growth.

For instance, CytoDyn Inc., a biotech firm developing humanized CCR5 monoclonal antibodies for several therapeutic indications, received FDA approval for its Investigation New Drug (IND) submission and is allowed to start a phase 1b/2 trial for metastatic Triple-Negative Breast Cancer (TNBC). This disease subtype is one of the leading causes of cancer deaths across the globe and it accounts for around 10 % of the overall cases. The firm has identified several trial sites and aims to dose a few patients and expects to have initial readout during the first quarter of 2019. Changes in the number of Circulating Tumor Cells (CTCs) will be assessed every 21 days throughout the trial.

Browse Details of Report @ https://www.hexaresearch.com/research-report/breast-cancer-market

Breast cancer is detected during a screening test or after the patient notices a lump, which is the most common physical sign. According to the World Health organization (WHO), every year, about 200,000 new cases of breast cancer are diagnosed globally and this number is likely to increase in future. Some of the major types of breast cancer are ductal carcinoma in situ (DCIS), Invasive Ductal Carcinoma (IDC), and lobular carcinoma. Invasive ductal carcinoma hold a major share in the market owing to growing prevalence of IDC, government support, and initiatives undertaken to increase awareness among patients. Furthermore, unmet clinical needs in treatment of IDC has compelled manufacturers to conduct rigorous R&D activities. Chemotherapy, targeted, surgery and radiation, hormone, and biologic therapies are some of the most popular treatments for the disease.

North America has emerged as the prominent region in the market on account of changing lifestyle, growing prevalence of the disease, and presence of leading companies in U.S. Europe is likely to emerge highly lucrative over the coming years as a result of increased healthcare expenditure and technological developments. Countries, including Germany, France, and U.K., are some of the key revenue-generating economies in Europe.

Asia pacific is also projected to witness a considerable growth over the next few years owing to rapidly developing healthcare infrastructure and rising consumer disposable income. Moreover, ongoing awareness programs about breast cancer and available treatments by governments in the emerging countries, such as China and India are estimated to foster the growth.

Companies are adopting several business strategies, such as novel product development, technological advancements, and M&A in order to strengthen their foothold in the industry. For example, FDA recently approved the Investigational New Drug (IND) application for Athenex’s oral form of Eribulin. It is an anticancer drug promoted by Eisai Company under the brand name Halaven and can effectively treat metastatic breast cancer and liposarcoma. The company is allowed to initiate clinical trial program, which is expected to start in the first half of 2019. Other targeted therapies introduced to treat breast cancer include Perjeta (pertuzumab) and Kadcyla (T-DM1), which is a human antibody-drug conjugate. Leading companies operating in the global breast cancer market include Pfizer, Inc.; Novartis AG; Apthera, Inc.; BioNumerik Pharmaceuticals, Inc.; Eli Lilly and Company; and Oncothyreon, Inc.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com

Germany Remote Patient Monitoring Devices Market Trends and Growth Forecasts, 2025

15 January 2019, The Germany Remote Patient Monitoring Devices Market size is expected to reach USD 120.4 million by 2025. This growth is attributed to rising population and trend of independent living, along with demand for cost-effective treatment and quality care. Remote patient monitoring devices are used for managing and monitoring a wide array of health conditions. These devices find application in chronic disease management, care integrator, progress tracker, an early warning system, capacity builder, and confidence builder.

Stringent government policies and favorable regulations by WHO in Germany regarding usage of remote patient monitoring devices are encouraging companies to develop drugs for treatment of chronic diseases. These diseases include cardiovascular diseases (CVDs), cancer, diabetes mellitus (DM), and chronic respiratory diseases. Penetration of remote patient monitoring devices in the German market supports local clinical research organizations (CROs) in their clinical research trials and ensures ease of monitoring, which facilitates drug discovery process.

Browse Details of Report @ https://www.hexaresearch.com/research-report/germany-remote-patient-monitoring-device-market

Thus, growing cases of chronic disorders are expected to serve as a high impact rendering factor for the Germany remote patient monitoring device industry. Cancer, CVDs, sleep disorder, and weight management and fitness monitoring are the key application segments analyzed in the Germany remote patient monitoring devices industry. Cardiovascular diseases segment is one of the largest application segments. This is mainly due to increasing number of patients suffering from diseases such as cardiac hypertension as they need regular blood pressure monitoring due to frequent fluctuations.

The use of remote patient monitoring devices in post-acute care aids in self-health management. Increasing demand for self-management skills and tools is projected to propel the market growth in the next few years. Escalating demand for independent care, especially in post-operative care is further anticipated to be a major factor driving the industry growth. Growing geriatric population, as they are highly susceptible to chronic conditions, such as diabetes and CVDs is also expected to fuel industry demand.

Cancer patients need continuous monitoring for evaluating their progress with regard to the prescribed treatment plan. Continuous monitoring enables doctors to evaluate and vary the dosage to eradicate tumor cells. Government initiatives such as various campaigns, health insurance policies, and reimbursement policies for medical devices present growth opportunities for the market, thereby augmenting the product demand. Moreover, advancements in technology, introduction of affordable and efficient devices, and improving healthcare infrastructure due to rapid economic growth would also propel market expansion.

The Germany remote patient monitoring device market is highly competitive and led by Medtronic Plc and St. Jude Medical, Inc. Other key companies are Boston Scientific Corporation, Covidien Ltd., and Philips Healthcare. Mergers and acquisitions are the key strategies undertaken by most of these companies to diversify their product portfolio and gain market share in the coming years.

Hexa Research has segmented the Germany remote patient monitoring devices market report based on product type, application and end use:

Segmentation by Product Type

    • Vital Sign Monitors

    • Specialized Monitors

Segmentation by Application

    • Cancer

    • Cardiovascular Diseases

    • Diabetes

    • Sleep Disorder

    • Weight Management

    • Fitness Monitoring

Segmentation by End Use

    • Hospital-based Patients

    • Ambulatory Patients

    • Home Healthcare

Key players analyzed:

    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

    • Nihon Kohden Corporation

    • Omron Corporation

    • OSI Systems, Inc.

    • Koninklijke Philips N.V.

    • Welch Allyn, Inc.

    • ALTEN Calsoft Labs

    • Smiths Medical, Inc.

    • Abbott Laboratories

    • American TeleCare, Inc.

    • Boston Scientific Corporation

    • Dräger Medical

    • GE Healthcare

    • Honeywell Life Care Solutions

    • Johnson & Johnson Services, Inc.

    • LifeWatch AG

    • Masimo

    • Medtronic PLC

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com

Oligonucleotide Testing Market - Current Trends and Growth Opportunities till 2024

28 November 2018, The global Oligonucleotide Testing Market to reach USD 1,746.52 million by 2024, owing to the increasing research and development activities in the field of oligonucleotide. For instance, nowadays, multifunctional oligonucleotide based aptamer molecules are widely studied biomedical class among scientists across the globe. Due to its unique chemistry and potential advantages compared to currently available drugs (i.e. antibodies), aptamer became one of the most budding market for the future period.

With the rising concept of oligonucleotide as diagnostic, research and therapeutic agent, it is noticed that companies investigating the potential of oligonucleotide is going up. Number of small companies or start-ups entering the market is continuously increasing due to its potential advantages. Over the past few years, there has been explosive growth in number of research article published in the area of oligonucleotide and its products.

Browse Details of Report @ https://www.hexaresearch.com/research-report/oligonucleotide-testing-market

According to the open access journal Multidisciplinary Digital Publishing Institute (MDPI AG), in 1995, there were not more than 200 research articles on aptamers. Compare to this, now it is around 1800 research literatures published by scientist on aptamer assays or therapeutics. This number indicates that companies focusing on the oligonucleotide drugs is rising every year. This fact would in turn cause a surge in demand for oligonucleotide testing services, augmenting growth. However, strict regulatory framework is anticipated to hamper the market expansion to some extent.

Types segment is categorized into Instrument, Software, and Services. Among which, instrument segment captured the largest share of the total market. Introduction of technological advanced chromatographic columns coupled with increasing demand for oligonucleotide synthesis drive the segment growth. Instrument segment is further divided into liquid chromatography, mass chromatography and capillary electrophoresis. In terms of application, the market is segmented as research and commercial. Research segment capture the largest share owing to the strong product pipeline.

In 2016, North America dominated the market contributing a share of more than 40% in the revenue generated worldwide. The primary reason being the high growth of this region, particularly in the U.S. is the rising research and development activities on oligonucleotides. Asia pacific region was estimated to be the fastest growing region in the global market and is anticipated to grow at a CAGR of about 10.8% by 2024. The growing need for effective therapeutics, rising awareness level, coupled with the favorable government initiatives are expected to drive growth in this region.

Currently there are very less approved oligonucleotide drugs namely fomivirsen (Vitravene), pegaptanib (Macugen), and mipomersen (Kynamro). Of which mipomersen and fomivirsen acti through RNase H mediated cleavage of targeted RNA. These drugs were developed by Ionis Pharmaceuticals. As the number of drugs available in the market are less, the oligonucleotide pipeline is strong and is expected to show positive response over the projection period.

Technological advances in development of oligonucleotide products has been one of the major market driver. Oligonucleotide synthesis has undergone tremendous changes which has resulted in rapid synthesis and cost-effective techniques of oligomer synthesis. Improvement of synthesis methods which include high throughput synthesizers, better coupling reagents and new sets of protective amino groups has drastically changed the nucleotide synthesis chemistry. With rapid development in oligonucleotide synthesis, the testing market is also expected to show lucrative growth. The major players are focusing on quality, service and innovation and adopting strategies such as product portfolio expansion, capacity expansions, and development of new facilities to gain market share.

Hexa Research has segmented the global oligonucleotide testing market report based on product type, application and region:

Segmentation by Type, 2014 - 2024
    • Instrument
        • Liquid Chromatography
        • Mass Chromatography
        • Capillary Electrophoresis
    • Software
    • Service

Segmentation by application, 2014 - 2024
    • Research
    • Commercial

Segmentation by region, 2014 - 2024
    • North America
        • U.S.
    • Europe
        • Germany
        • UK
    • Asia Pacific
        • China
        • India
    • Rest of the world (RoW)

Key players analyzed:
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Integrated DNA Technologies, Inc.
    • Agilent Technologies
    • Bruker

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com

Herbal Medicine Market Size and Regional Outlook, 2024

22 November 2018 -

The global Herbal Medicine Market is expected to reach USD 117.02 billion by 2024, driven by rising popularity of herbal therapeutics compared to conventional drugs. The market for herbal medicines and remedies is anticipated to record profitable growth due to their cost-effectiveness as compared to allopathic ones.

In 2016, Europe was the largest market for traditional medicines, contributing to 40.8% of the share and is expected to retain its leadership during the forecast period due to shifting from conventional drugs to herbal products. Fewer side effects and low toxicity compared to allopathy products are expected to provide a competitive advantage over other medicines in the market. Additionally, ready acceptance of herbal products owing to its benefits is the key factor for market growth and is expected to play a significant role in future.

Increased preference of complementary and alternative medicine (CAM) among others has resulted in the growth of herbal medicines in Asia Pacific. Asia Pacific is expected to record the fastest CAGR of 6.8% over the forecast period. Furthermore, Europe is anticipated to generate maximum revenue over the forecast period due to increasing awareness created by various associations such as Association for Natural Medicine in Europe (AIME).

Browse Details of Report @ https://www.hexaresearch.com/research-report/global-herbal-medicine-market

Concerning product segment, tablets & capsules are expected to witness the fastest growth owing to increasing acceptance of tablets over extracts and powders. Furthermore, properties such as high dose accuracy essential for optimum therapeutic effect will, in turn, promote the herbalism market growth. The extracts segment is expected to grow at a lucrative rate as they show an immediate therapeutic effect on administration.

For instance, in geriatric patients, extracts and other liquid dosage forms are preferred for administration as tablets show delayed therapeutic effect. Furthermore, extracts provide high potency as they possess only the active ingredients and no fillers which are present in tablets & capsules.

The rigorous focus on developing better extraction and purification techniques by herbal medicine manufacturers is expected to fuel the market. Furthermore, respective governments are also introducing several strategies to promote the uptake of herbal medicine market. For instance, in July 2017, the Chinese Ministry of Science and Technology invested USD 12.5 million for development of herbal treatments for the treatment of cancer and HIV/AIDS.

Hexa Research has segmented the global herbal medicine market based on Product, Indication, and region:

Segmentation by Product, 2014 - 2024 (USD Billion)
• Tablets & Capsules
• Powders
• Extracts
• Others

Segmentation by Indication, 2014 - 2024 (USD Billion)
• Digestive Disorders
• Respiratory Disorders
• Blood Disorders
• Others

Segmentation by Region, 2014 - 2024 (USD Billion)
• North America
    • U.S.
• Europe
    • Germany
• Asia Pacific
    • China
    • India
• Central & South America
• Middle East and Africa

Key Players Analyzed
• TSUMURA & CO.
• Dr. Willmar Schwabe India Pvt. Ltd.
• Blackmores
• NATURE'S ANSWER
• Arkopharma
• Arizona Natural Products
• Herbal Africa
• Bio Botanica, Inc.
• Sidomuncul
• Nature Herbs

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com